A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti- Retroviral Activity of MK-8583 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2018
At a glance
- Drugs MK-8583 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 17 Oct 2018 Planned End Date changed from 26 Mar 2019 to 29 Mar 2019.
- 17 Oct 2018 Planned primary completion date changed from 26 Mar 2019 to 29 Mar 2019.
- 17 Oct 2018 Status changed from not yet recruiting to recruiting.